SlideShare a Scribd company logo
1 of 24
Download to read offline
Allocating Healthcare Budgets to 
        General Practices
   Peter C. Smith on behalf of PBRA team
     Imperial College Business School & 
          Centre for Health Policy




   http://www.nuffieldtrust.org.uk/projects/index.aspx?id=338
The Person‐based resource allocation 
           (PBRA) project
           (     )
• Led by Jennifer Dixon (Nuffield Trust) from
  Led by Jennifer Dixon (Nuffield Trust) from 
  2007
• Initial purpose was to develop budgets for
  Initial purpose was to develop budgets for 
  practice based commissioning based on 
  individual patient data
  individual patient data
• Coverage: secondary care, prescribing, 
  community health services
            i h lh        i
Reviews of resource allocation in English NHS 
                      Hospital and Community Health Services , 1976‐
                      Hospital and Community Health Services 1976‐ today

       Year         Name                         Allocations        Approximate    Years applied
                                                      to             population 
                                                                     population
                                                                        size
       1976         RAWP                           14 RHAs              3m         77/78 – 90/91
       1980         RoR
                    R R                            14 RHAs
                                                   14 RHA               3m
                                                                        3          91/92 –
                                                                                   91/92 94/95
       1993         University of                  14 RHAs              3m         95/96 – 01/02 
                    York                          192 DHAs            250,000

       2001         AREA                           303 PCTs           175,000      02/03 – 06/07
       2006         CARAN                          152 PCTs           350,000         07/08 –



Drawn from Bevan,  and Bevan and Van der Ven 
Drawn from Bevan, and Bevan and Van der Ven
Note:          RAWP = Resource Allocation Working Party
               RoR = Review of RAWP
               AREA = Allocation of Resources to English Areas
               CARAN = Combining Age Related Additional Needs (9)
                                                                                                    3
PBRA modelling principles
      PBRA modelling principles
• Use of individual‐level data on both users and 
  non‐users of health care services (entire English 
  population)
• Use of data from past NHS encounters to
  Use of data from past NHS encounters to 
  measure morbidity directly (via ICD chapters)
• Predict future expenditure at an individual level.
  Predict future expenditure at an individual level.
• Developed on samples of 5 million patients 
  registered within GP practices – models validated 
  on separate sample of 5 million patients. 
                     l f 5 illi       i
• Models further assessed by performance of 
  predictions at practice level
  predictions at practice level
Linking the data sets for analysis
      g                       y




                                     5
Modelling principles
  d lli     i i l

    Explanatory variables             Prediction variable



   2005/06            2006/07             2007/08




            Samples drawn from patients registered 1 April 2007



                                                                  6
Modelling
• Hospital‐based expenditure excluding maternity and 
  mental illness
• Modelled hospital expenditure in year t as a function 
  of:
   – Age and sex (36)
   – Diagnostic categories from hospital utilization in years t‐1
     and t‐2
     and t‐2 (152)
   – Attributed GP  and small area needs characteristics (135)
   – Attributed small area supply characteristics (63)
   – PCT (152)
          (   )
• Note: did not consider variables with potentially 
  adverse incentive effects, eg number of encounters
                              g
Summary results of a set of five models, predicting 
   costs for 2007/08 using data from 2005/06 & 2006/07
      t f 2007/08 i d t f            2005/06 & 2006/07

MODEL                                    R2 individual R2 practice
Model 1: age and gender                  0.0366        0.3444
Model 2 ‐ ADD:
      152 morbidity markers              0.1223        0.6084
Model 3 ‐ ADD:
      152 PCT dummies                    0.1227        0.7437
Model 4 ‐ ADD:
      135 attributed needs & 63 supply
      135 tt ib t d     d & 63      l    0.1230
                                         0 1230        0.7851
                                                       0 7851
Model 5 ‐ REDUCE TO:
      7 attributed needs & 3 supply
      7 attributed needs & 3 supply      0.1229
                                         0 1229        0.7735
                                                       0 7735
Type of       Variable name
variable
Individual    •   Age and gender
              •   157 ICD‐10 groups


Attributed 
Attributed    •   Persons in social rented housing
                  Persons in social rented housing
needs
              •   All disability allowance claimants
              •   Persons aged 16 74 with no qualifications (age standardised)
                  Persons aged 16‐74 with no qualifications (age standardised)
              •   Mature city professionals
              •   Proportion of students in the population
              •   Whether the person had a privately funded inpatient episode of care 
                  provided by the NHS in previous two years
              •   Asthma prevalence rate


Attributed    •   Quality of stroke care (primary and secondary care), by weighted 
supply            population
              •   Accessibility to MRI scanner
              •   Catchment population of the hospital trust that supplied the practice 
                  with the largest number of inpatient admissions
Using the formula to allocate to 
                practices
• ‘Freeze’ supply variables at national levels
              pp y
• For each individual, calculate predicted NHS 
  hospital costs
• For each practice calculate average costs in each 
  age/sex category
• Assign age/sex specific averages to all individuals
  Assign age/sex specific averages to all individuals 
  in practice
   – To address data lags and changes in registration
• Share out PCT budget according to practices’ total 
  predicted expenditure
Distance from target and practice size
                                               for the new model and practices with more than 500 patients
                                     2
  DF index: relative to England mean
                            1.5
                      o
       .5          1
   FT
0




                                         0                   10000             20000             30000       40000
                                                                 practice size: number of patients
                                         Excludes the 16 practices with a DFT index > 2.
Distance from target
            Distance from target
                             Percentage of practices more than 
                             Percentage of practices more than
                                    x% away from target
                            > +/‐ 5% > +/‐ 10%       > +/‐ 20%
DFT relative to PCT 
mean                         61.1       34.6          14.0

DFT relative to national 
mean                         72.5       48.9          20.9




                                                              12
Phase III Objectives: in progress
  Phase III Objectives: in progress
• Refresh existing PBRA model using more
  Refresh existing PBRA model using more 
  recent data (for allocations 2011/12)
• Develop improved PBRA model (for allocations
  Develop improved PBRA model (for allocations 
  2012/13) 
• Model a variety of risk sharing arrangements
  Model a variety of risk sharing arrangements 
  (to inform shadow GP Consortia and NHS 
  Commissioning Board)
• Develop a final PBRA formula (for allocations 
  2013/14)
Basic model


    Explanatory variables      Prediction variable




2007/08              2008/09     2009/10
Data lag

2007/08   2008/09   2009/10   2010/11   2011/12   2012/13
GP budgets and risk:
              we’ve been here before
                ’ b      h    b f
•   GP fundholding c.1991
                  g
•   Total fundholding c.1995
•   ‘Primary Care Groups’ c.1998
•   Practice based commissioning c.2002


Martin, S., Rice, N. and Smith, P. (1998), “Risk and the general 
  practitioner budget holder”, Social Science and Medicine, 47(10), 
  1547‐1554.
Smith, P. (1999), “Setting budgets for general practice in the New NHS”, 
  British Medical Journal, 318, 776‐779.
Fundholding
• Relatively generous budgets
  Relatively generous budgets
• Limited set of elective conditions plus 
  prescribing covered
  prescribing covered
• Per patient limit £6000
• Overspends largely borne by Health Authority
• Underspends kept by practice for patient 
          p        p yp              p
  services
• A very ‘soft’ budget
  A very  soft budget
Decomposing the variation in practice 
          expenditure 
                 d
• The formula captures average clinical responses 
                p            g             p
  to measured patient and area characteristics. 
  Therefore any variation from the formula will be 
  due to:
  due to:
  – Variations in clinical practice;
  – Variations in the prices of treatments used by the 
    practice;
  – Imperfections in the formula caused by known patient 
    characteristics that are not captured in the formula;
                                     p                  ;
  – Random (chance) variations in levels of sickness 
    within the practice population.
High cost cases
                                High cost cases
          practices
 umber of p
Nu




                      Percentage of cases over £20K per person per year   19
Sampled from patients (10m) within a 20% random sample of all patients
              100 replications for each consortium size
             Consortium size increased in units of 10,000

                                         40                                Consortia risk profile
                                                                                          p
              sortium risk per capita(£)



                                                         Upper 95% C.I.
                                20




                                     14
                        0




                                                                                                                     Average risk


                             ‐13.5
              -20
              -
           Cons




                                                         Lower 95% C.I.
       -40




                                              0               100000       200000        300000         400000   500000
                                                                            Consortium list size

                                                                          Average risk              Lower CI
                                                                          Upper CI
                                              Simulations from all data
                                              Risk smoothed over time - predicted versus actual expenditure
Consortia risk profile
                                 Consortium size                            Consortium size
                                    10000                                      100000
              .6




                                                               .6
              .4




                                                               .4
              .2




                                                               .2
              0




                                                               0
    ability




                   0       2       4       6        8     10        0   2    4        6       8   10
Proba




                                 Consortium size                            Consortium size
                                    300000                                     500000
              .6




                                                               .6
              .4
               4




                                                               .4
                                                                4
              .2




                                                               .2
              0




                                                               0
                   0       2       4       6        8     10        0   2    4        6       8   10
                                                   Percentage Variation
              Simulations from all data
              Probability f
              P b bilit of more th an X percent variation f
                                than          t    i ti from annual b d t
                                                                  l budget


                               Acknowledgement: Nigel Rice and Hugh Gravelle
Consortia risk profile
                                  Consortium size                                  Consortium size
                                      10000                                            50000
               .6




                                                                  .6
               .4




                                                                  .4
               .2




                                                                  .2
               0




                                                                  0
  obability




                    0       2       4        6        8      10        0       2     4        6      8   10
                                  Consortium size                                  Consortium size
Pro




                                     100000                                           150000
               .6




                                                                  .6
               .4




                                                                  .4
               .2
                2




                                                                  .2
                                                                   2
               0




                                                                  0
                    0       2       4        6        8      10        0       2     4        6      8   10
                                                    Percentage Variation
                                                 Omit £100k                    Omit £150k
              Probability of more than an X percent variation from annual budget
              Simulations omitting hi h cost patients f
              Si l ti       itti high      t ti t from practice li t
                                                           ti lists


                                  Acknowledgement: Nigel Rice and Hugh Gravelle
Some possible consequences of ‘hard’ 
        budget constraints
        b d
• Practices that perceive that their expenditure will fall below their 
  budget may “spend up” in order to protect their budgetary position 
  b d t         “     d ”i       d t        t t th i b d t          iti
  in future years;
• Practices that perceive that their expenditure will exceed their 
  budget may be thrown into crisis as they seek to conform to the 
  budget may be thrown into crisis as they seek to conform to the
  budget;
• Patients may be treated inequitably.  Different practices will be 
  under different budgetary pressures, and so may adopt different 
  treatment practices.  
• Within a practice, choice of treatment may vary over the course of 
  a year if the practice’s perception of its budgetary position changes.
• G
  General practices may adopt a variety of defensive stratagems, such 
          l       i         d         i      fd f i                     h
  as cream skimming patients they perceive to be healthier than 
  implied by their capitation payment.
Some budgetary risk management 
               strategies
•   Pooling practices
•   Pooling years
•   Excluding predictably expensive patients
•   ‘Carving out’ certain procedures or services
     Carving out certain procedures or services
•   Analysis of reasons for variations from budgets
•   Allowing some reinsurance of risk
    –   Limiting liability on individual episode
    –   Limiting liability on individual patient
    –   Risk sharing
    –   Retention of a contingency fund
    –   Etc
• Making sanctions and rewards proportionate
       g                       p p

More Related Content

Similar to Peter Smith: Allocating healthcare budgets to general practices

Making the most of your PROM data, pop up uni, 10am, 2 september 2015
Making the most of your PROM data, pop up uni, 10am, 2 september 2015Making the most of your PROM data, pop up uni, 10am, 2 september 2015
Making the most of your PROM data, pop up uni, 10am, 2 september 2015NHS England
 
How diagnostics can drive efficiency within the NHS
How diagnostics can drive efficiency within the NHSHow diagnostics can drive efficiency within the NHS
How diagnostics can drive efficiency within the NHSWalt Whitman
 
Orlando Agrippa, Draper & Dash at "Journeys of Health-Tech Innovation" Nov 3...
Orlando Agrippa, Draper & Dash  at "Journeys of Health-Tech Innovation" Nov 3...Orlando Agrippa, Draper & Dash  at "Journeys of Health-Tech Innovation" Nov 3...
Orlando Agrippa, Draper & Dash at "Journeys of Health-Tech Innovation" Nov 3...Health-Tech Innovation LABS
 
Rntcp with emphasis on recent advances
Rntcp with emphasis on recent advancesRntcp with emphasis on recent advances
Rntcp with emphasis on recent advancesSourav Pattanayak
 
Eugm 2011 mehta - adaptive designs for phase 3 oncology trials
Eugm 2011   mehta - adaptive designs for phase 3 oncology trialsEugm 2011   mehta - adaptive designs for phase 3 oncology trials
Eugm 2011 mehta - adaptive designs for phase 3 oncology trialsCytel USA
 
Therapeutic Area Standards: Reflections on Oncology Standards and What is Nee...
Therapeutic Area Standards: Reflections on Oncology Standards and What is Nee...Therapeutic Area Standards: Reflections on Oncology Standards and What is Nee...
Therapeutic Area Standards: Reflections on Oncology Standards and What is Nee...Cytel
 
Seven Day services - Healthcare Science presentation (Blower)
Seven Day services - Healthcare Science presentation (Blower)Seven Day services - Healthcare Science presentation (Blower)
Seven Day services - Healthcare Science presentation (Blower)AHCS
 
Technology Assessment/Outcome & Cost-Effectiveness Analysis 2016
Technology Assessment/Outcome & Cost-Effectiveness Analysis 2016Technology Assessment/Outcome & Cost-Effectiveness Analysis 2016
Technology Assessment/Outcome & Cost-Effectiveness Analysis 2016evadew1
 
SGRT: Important Player in Oligometastatic Treatments
SGRT: Important Player in Oligometastatic TreatmentsSGRT: Important Player in Oligometastatic Treatments
SGRT: Important Player in Oligometastatic TreatmentsSGRT Community
 
Gavin MacColl: Anticipatory care planning in primary care
Gavin MacColl: Anticipatory care planning in primary careGavin MacColl: Anticipatory care planning in primary care
Gavin MacColl: Anticipatory care planning in primary careNuffield Trust
 
Meridian Group_Final Business Plan
Meridian Group_Final Business PlanMeridian Group_Final Business Plan
Meridian Group_Final Business PlanChris MacFadyen, MHA
 
Linacs radiation treatment machine, syndicate 9 (1)
Linacs radiation treatment machine, syndicate 9 (1)Linacs radiation treatment machine, syndicate 9 (1)
Linacs radiation treatment machine, syndicate 9 (1)TopanArdiansyah1
 
4 Sally Diagnostics UK May 2016 v3.1.pptx
4 Sally Diagnostics UK May 2016 v3.1.pptx4 Sally Diagnostics UK May 2016 v3.1.pptx
4 Sally Diagnostics UK May 2016 v3.1.pptxDESMONDEZIEKE1
 
Icru 29,50 &62
Icru 29,50 &62Icru 29,50 &62
Icru 29,50 &62Dhiman Das
 
Technology Assessment, Outcomes Research and Economic Analyses
Technology Assessment, Outcomes Research and Economic AnalysesTechnology Assessment, Outcomes Research and Economic Analyses
Technology Assessment, Outcomes Research and Economic Analysesevadew1
 
How Centers Can​ Thrive in the Modern Era
How Centers Can​ Thrive in the Modern EraHow Centers Can​ Thrive in the Modern Era
How Centers Can​ Thrive in the Modern EraSGRT Community
 
How Centers Can​ Thrive in the Modern Era
How Centers Can​ Thrive in the Modern EraHow Centers Can​ Thrive in the Modern Era
How Centers Can​ Thrive in the Modern EraRachaelSmith830794
 

Similar to Peter Smith: Allocating healthcare budgets to general practices (20)

Making the most of your PROM data, pop up uni, 10am, 2 september 2015
Making the most of your PROM data, pop up uni, 10am, 2 september 2015Making the most of your PROM data, pop up uni, 10am, 2 september 2015
Making the most of your PROM data, pop up uni, 10am, 2 september 2015
 
How diagnostics can drive efficiency within the NHS
How diagnostics can drive efficiency within the NHSHow diagnostics can drive efficiency within the NHS
How diagnostics can drive efficiency within the NHS
 
Orlando Agrippa, Draper & Dash at "Journeys of Health-Tech Innovation" Nov 3...
Orlando Agrippa, Draper & Dash  at "Journeys of Health-Tech Innovation" Nov 3...Orlando Agrippa, Draper & Dash  at "Journeys of Health-Tech Innovation" Nov 3...
Orlando Agrippa, Draper & Dash at "Journeys of Health-Tech Innovation" Nov 3...
 
Rntcp with emphasis on recent advances
Rntcp with emphasis on recent advancesRntcp with emphasis on recent advances
Rntcp with emphasis on recent advances
 
Eugm 2011 mehta - adaptive designs for phase 3 oncology trials
Eugm 2011   mehta - adaptive designs for phase 3 oncology trialsEugm 2011   mehta - adaptive designs for phase 3 oncology trials
Eugm 2011 mehta - adaptive designs for phase 3 oncology trials
 
Therapeutic Area Standards: Reflections on Oncology Standards and What is Nee...
Therapeutic Area Standards: Reflections on Oncology Standards and What is Nee...Therapeutic Area Standards: Reflections on Oncology Standards and What is Nee...
Therapeutic Area Standards: Reflections on Oncology Standards and What is Nee...
 
Seven Day services - Healthcare Science presentation (Blower)
Seven Day services - Healthcare Science presentation (Blower)Seven Day services - Healthcare Science presentation (Blower)
Seven Day services - Healthcare Science presentation (Blower)
 
Technology Assessment/Outcome & Cost-Effectiveness Analysis 2016
Technology Assessment/Outcome & Cost-Effectiveness Analysis 2016Technology Assessment/Outcome & Cost-Effectiveness Analysis 2016
Technology Assessment/Outcome & Cost-Effectiveness Analysis 2016
 
SGRT: Important Player in Oligometastatic Treatments
SGRT: Important Player in Oligometastatic TreatmentsSGRT: Important Player in Oligometastatic Treatments
SGRT: Important Player in Oligometastatic Treatments
 
Gavin MacColl: Anticipatory care planning in primary care
Gavin MacColl: Anticipatory care planning in primary careGavin MacColl: Anticipatory care planning in primary care
Gavin MacColl: Anticipatory care planning in primary care
 
Meridian Group_Final Business Plan
Meridian Group_Final Business PlanMeridian Group_Final Business Plan
Meridian Group_Final Business Plan
 
Linacs radiation treatment machine, syndicate 9 (1)
Linacs radiation treatment machine, syndicate 9 (1)Linacs radiation treatment machine, syndicate 9 (1)
Linacs radiation treatment machine, syndicate 9 (1)
 
Reintroductioncompetition
ReintroductioncompetitionReintroductioncompetition
Reintroductioncompetition
 
4 Sally Diagnostics UK May 2016 v3.1.pptx
4 Sally Diagnostics UK May 2016 v3.1.pptx4 Sally Diagnostics UK May 2016 v3.1.pptx
4 Sally Diagnostics UK May 2016 v3.1.pptx
 
Nlep
NlepNlep
Nlep
 
Icru 29,50 &62
Icru 29,50 &62Icru 29,50 &62
Icru 29,50 &62
 
Technology Assessment, Outcomes Research and Economic Analyses
Technology Assessment, Outcomes Research and Economic AnalysesTechnology Assessment, Outcomes Research and Economic Analyses
Technology Assessment, Outcomes Research and Economic Analyses
 
How Centers Can​ Thrive in the Modern Era
How Centers Can​ Thrive in the Modern EraHow Centers Can​ Thrive in the Modern Era
How Centers Can​ Thrive in the Modern Era
 
How Centers Can​ Thrive in the Modern Era
How Centers Can​ Thrive in the Modern EraHow Centers Can​ Thrive in the Modern Era
How Centers Can​ Thrive in the Modern Era
 
Wilcox JN - AIMRADIAL 2013 - Medtronic perspective
Wilcox JN - AIMRADIAL 2013 - Medtronic perspectiveWilcox JN - AIMRADIAL 2013 - Medtronic perspective
Wilcox JN - AIMRADIAL 2013 - Medtronic perspective
 

More from Nuffield Trust

Transforming outpatient services - Nuffield Trust/NHS Improvement Event
Transforming outpatient services - Nuffield Trust/NHS Improvement EventTransforming outpatient services - Nuffield Trust/NHS Improvement Event
Transforming outpatient services - Nuffield Trust/NHS Improvement EventNuffield Trust
 
13 reasons to spend more on health and social care
13 reasons to spend more on health and social care 13 reasons to spend more on health and social care
13 reasons to spend more on health and social care Nuffield Trust
 
Energising your workforce in the face of adversity
Energising your workforce in the face of adversityEnergising your workforce in the face of adversity
Energising your workforce in the face of adversityNuffield Trust
 
Shifting the balance of care: great expectations
Shifting the balance of care: great expectations Shifting the balance of care: great expectations
Shifting the balance of care: great expectations Nuffield Trust
 
Automation, Employment, and Health Care
Automation, Employment, and Health Care Automation, Employment, and Health Care
Automation, Employment, and Health Care Nuffield Trust
 
Public perspectives on the NHS and social care
Public perspectives on the NHS and social carePublic perspectives on the NHS and social care
Public perspectives on the NHS and social careNuffield Trust
 
Evaluation of the Integrated Care and Support Pioneers Programme
Evaluation of the Integrated Care and Support Pioneers ProgrammeEvaluation of the Integrated Care and Support Pioneers Programme
Evaluation of the Integrated Care and Support Pioneers ProgrammeNuffield Trust
 
Ensuring success for new models of care
Ensuring success for new models of careEnsuring success for new models of care
Ensuring success for new models of careNuffield Trust
 
Effectiveness of the current dominant approach to integrated care in the NHS
Effectiveness of the current dominant approach to integrated care in the NHSEffectiveness of the current dominant approach to integrated care in the NHS
Effectiveness of the current dominant approach to integrated care in the NHSNuffield Trust
 
Providing actionable healthcare analytics at scale: Understanding improvement...
Providing actionable healthcare analytics at scale: Understanding improvement...Providing actionable healthcare analytics at scale: Understanding improvement...
Providing actionable healthcare analytics at scale: Understanding improvement...Nuffield Trust
 
Local and national uses of data
Local and national uses of dataLocal and national uses of data
Local and national uses of dataNuffield Trust
 
Applied use of CUSUMs in surveillance
Applied use of CUSUMs in surveillanceApplied use of CUSUMs in surveillance
Applied use of CUSUMs in surveillanceNuffield Trust
 
Evaluating new models of care: Improvement Analytics Unit
Evaluating new models of care: Improvement Analytics UnitEvaluating new models of care: Improvement Analytics Unit
Evaluating new models of care: Improvement Analytics UnitNuffield Trust
 
Learning from the Care Quality Commission
Learning from the Care Quality CommissionLearning from the Care Quality Commission
Learning from the Care Quality CommissionNuffield Trust
 
Real-time monitoring and the data trap
Real-time monitoring and the data trapReal-time monitoring and the data trap
Real-time monitoring and the data trapNuffield Trust
 
Monitoring quality of care: making the most of data
Monitoring quality of care: making the most of dataMonitoring quality of care: making the most of data
Monitoring quality of care: making the most of dataNuffield Trust
 
Providing actionable healthcare analytics at scale: Insights from the Nationa...
Providing actionable healthcare analytics at scale: Insights from the Nationa...Providing actionable healthcare analytics at scale: Insights from the Nationa...
Providing actionable healthcare analytics at scale: Insights from the Nationa...Nuffield Trust
 
Providing actionable healthcare analytics at scale: A perspective from stroke...
Providing actionable healthcare analytics at scale: A perspective from stroke...Providing actionable healthcare analytics at scale: A perspective from stroke...
Providing actionable healthcare analytics at scale: A perspective from stroke...Nuffield Trust
 
New Models of General Practice: Practical and policy lessons
New Models of General Practice: Practical and policy lessonsNew Models of General Practice: Practical and policy lessons
New Models of General Practice: Practical and policy lessonsNuffield Trust
 

More from Nuffield Trust (20)

Transforming outpatient services - Nuffield Trust/NHS Improvement Event
Transforming outpatient services - Nuffield Trust/NHS Improvement EventTransforming outpatient services - Nuffield Trust/NHS Improvement Event
Transforming outpatient services - Nuffield Trust/NHS Improvement Event
 
13 reasons to spend more on health and social care
13 reasons to spend more on health and social care 13 reasons to spend more on health and social care
13 reasons to spend more on health and social care
 
Energising your workforce in the face of adversity
Energising your workforce in the face of adversityEnergising your workforce in the face of adversity
Energising your workforce in the face of adversity
 
Shifting the balance of care: great expectations
Shifting the balance of care: great expectations Shifting the balance of care: great expectations
Shifting the balance of care: great expectations
 
Automation, Employment, and Health Care
Automation, Employment, and Health Care Automation, Employment, and Health Care
Automation, Employment, and Health Care
 
Public perspectives on the NHS and social care
Public perspectives on the NHS and social carePublic perspectives on the NHS and social care
Public perspectives on the NHS and social care
 
Evaluation of the Integrated Care and Support Pioneers Programme
Evaluation of the Integrated Care and Support Pioneers ProgrammeEvaluation of the Integrated Care and Support Pioneers Programme
Evaluation of the Integrated Care and Support Pioneers Programme
 
Ensuring success for new models of care
Ensuring success for new models of careEnsuring success for new models of care
Ensuring success for new models of care
 
Effectiveness of the current dominant approach to integrated care in the NHS
Effectiveness of the current dominant approach to integrated care in the NHSEffectiveness of the current dominant approach to integrated care in the NHS
Effectiveness of the current dominant approach to integrated care in the NHS
 
Providing actionable healthcare analytics at scale: Understanding improvement...
Providing actionable healthcare analytics at scale: Understanding improvement...Providing actionable healthcare analytics at scale: Understanding improvement...
Providing actionable healthcare analytics at scale: Understanding improvement...
 
Local and national uses of data
Local and national uses of dataLocal and national uses of data
Local and national uses of data
 
Applied use of CUSUMs in surveillance
Applied use of CUSUMs in surveillanceApplied use of CUSUMs in surveillance
Applied use of CUSUMs in surveillance
 
Engaging with data
Engaging with dataEngaging with data
Engaging with data
 
Evaluating new models of care: Improvement Analytics Unit
Evaluating new models of care: Improvement Analytics UnitEvaluating new models of care: Improvement Analytics Unit
Evaluating new models of care: Improvement Analytics Unit
 
Learning from the Care Quality Commission
Learning from the Care Quality CommissionLearning from the Care Quality Commission
Learning from the Care Quality Commission
 
Real-time monitoring and the data trap
Real-time monitoring and the data trapReal-time monitoring and the data trap
Real-time monitoring and the data trap
 
Monitoring quality of care: making the most of data
Monitoring quality of care: making the most of dataMonitoring quality of care: making the most of data
Monitoring quality of care: making the most of data
 
Providing actionable healthcare analytics at scale: Insights from the Nationa...
Providing actionable healthcare analytics at scale: Insights from the Nationa...Providing actionable healthcare analytics at scale: Insights from the Nationa...
Providing actionable healthcare analytics at scale: Insights from the Nationa...
 
Providing actionable healthcare analytics at scale: A perspective from stroke...
Providing actionable healthcare analytics at scale: A perspective from stroke...Providing actionable healthcare analytics at scale: A perspective from stroke...
Providing actionable healthcare analytics at scale: A perspective from stroke...
 
New Models of General Practice: Practical and policy lessons
New Models of General Practice: Practical and policy lessonsNew Models of General Practice: Practical and policy lessons
New Models of General Practice: Practical and policy lessons
 

Recently uploaded

Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfSreeja Cherukuru
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAAjennyeacort
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 
systemic bacteriology (7)............pptx
systemic bacteriology (7)............pptxsystemic bacteriology (7)............pptx
systemic bacteriology (7)............pptxEyobAlemu11
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfDivya Kanojiya
 
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdfSGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdfHongBiThi1
 
maternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortalitymaternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortalityhardikdabas3
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
 
world health day presentation ppt download
world health day presentation ppt downloadworld health day presentation ppt download
world health day presentation ppt downloadAnkitKumar311566
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxpdamico1
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptxMohamed Rizk Khodair
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurNavdeep Kaur
 
low cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptxlow cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptxdrashraf369
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Badalona Serveis Assistencials
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Prerana Jadhav
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiGoogle
 
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfMedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfSasikiranMarri
 
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMAANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMADivya Kanojiya
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdfDolisha Warbi
 

Recently uploaded (20)

Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 
systemic bacteriology (7)............pptx
systemic bacteriology (7)............pptxsystemic bacteriology (7)............pptx
systemic bacteriology (7)............pptx
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdf
 
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdfSGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
 
maternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortalitymaternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortality
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
 
world health day presentation ppt download
world health day presentation ppt downloadworld health day presentation ppt download
world health day presentation ppt download
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptx
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
 
low cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptxlow cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptx
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali Rai
 
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfMedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
 
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMAANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
 

Peter Smith: Allocating healthcare budgets to general practices

  • 1. Allocating Healthcare Budgets to  General Practices Peter C. Smith on behalf of PBRA team Imperial College Business School &  Centre for Health Policy http://www.nuffieldtrust.org.uk/projects/index.aspx?id=338
  • 2. The Person‐based resource allocation  (PBRA) project ( ) • Led by Jennifer Dixon (Nuffield Trust) from Led by Jennifer Dixon (Nuffield Trust) from  2007 • Initial purpose was to develop budgets for Initial purpose was to develop budgets for  practice based commissioning based on  individual patient data individual patient data • Coverage: secondary care, prescribing,  community health services i h lh i
  • 3. Reviews of resource allocation in English NHS  Hospital and Community Health Services , 1976‐ Hospital and Community Health Services 1976‐ today Year Name Allocations  Approximate  Years applied to population  population size 1976 RAWP 14 RHAs 3m 77/78 – 90/91 1980 RoR R R 14 RHAs 14 RHA 3m 3 91/92 – 91/92 94/95 1993 University of  14 RHAs 3m 95/96 – 01/02  York 192 DHAs 250,000 2001 AREA 303 PCTs 175,000 02/03 – 06/07 2006 CARAN 152 PCTs 350,000 07/08 – Drawn from Bevan,  and Bevan and Van der Ven  Drawn from Bevan, and Bevan and Van der Ven Note: RAWP = Resource Allocation Working Party RoR = Review of RAWP AREA = Allocation of Resources to English Areas CARAN = Combining Age Related Additional Needs (9) 3
  • 4. PBRA modelling principles PBRA modelling principles • Use of individual‐level data on both users and  non‐users of health care services (entire English  population) • Use of data from past NHS encounters to Use of data from past NHS encounters to  measure morbidity directly (via ICD chapters) • Predict future expenditure at an individual level. Predict future expenditure at an individual level. • Developed on samples of 5 million patients  registered within GP practices – models validated  on separate sample of 5 million patients.  l f 5 illi i • Models further assessed by performance of  predictions at practice level predictions at practice level
  • 6. Modelling principles d lli i i l Explanatory variables Prediction variable 2005/06 2006/07 2007/08 Samples drawn from patients registered 1 April 2007 6
  • 7. Modelling • Hospital‐based expenditure excluding maternity and  mental illness • Modelled hospital expenditure in year t as a function  of: – Age and sex (36) – Diagnostic categories from hospital utilization in years t‐1 and t‐2 and t‐2 (152) – Attributed GP  and small area needs characteristics (135) – Attributed small area supply characteristics (63) – PCT (152) ( ) • Note: did not consider variables with potentially  adverse incentive effects, eg number of encounters g
  • 8. Summary results of a set of five models, predicting  costs for 2007/08 using data from 2005/06 & 2006/07 t f 2007/08 i d t f 2005/06 & 2006/07 MODEL R2 individual R2 practice Model 1: age and gender 0.0366 0.3444 Model 2 ‐ ADD: 152 morbidity markers   0.1223 0.6084 Model 3 ‐ ADD: 152 PCT dummies  0.1227 0.7437 Model 4 ‐ ADD: 135 attributed needs & 63 supply 135 tt ib t d d & 63 l 0.1230 0 1230 0.7851 0 7851 Model 5 ‐ REDUCE TO: 7 attributed needs & 3 supply 7 attributed needs & 3 supply 0.1229 0 1229 0.7735 0 7735
  • 9. Type of  Variable name variable Individual • Age and gender • 157 ICD‐10 groups Attributed  Attributed • Persons in social rented housing Persons in social rented housing needs • All disability allowance claimants • Persons aged 16 74 with no qualifications (age standardised) Persons aged 16‐74 with no qualifications (age standardised) • Mature city professionals • Proportion of students in the population • Whether the person had a privately funded inpatient episode of care  provided by the NHS in previous two years • Asthma prevalence rate Attributed  • Quality of stroke care (primary and secondary care), by weighted  supply population • Accessibility to MRI scanner • Catchment population of the hospital trust that supplied the practice  with the largest number of inpatient admissions
  • 10. Using the formula to allocate to  practices • ‘Freeze’ supply variables at national levels pp y • For each individual, calculate predicted NHS  hospital costs • For each practice calculate average costs in each  age/sex category • Assign age/sex specific averages to all individuals Assign age/sex specific averages to all individuals  in practice – To address data lags and changes in registration • Share out PCT budget according to practices’ total  predicted expenditure
  • 11. Distance from target and practice size for the new model and practices with more than 500 patients 2 DF index: relative to England mean 1.5 o .5 1 FT 0 0 10000 20000 30000 40000 practice size: number of patients Excludes the 16 practices with a DFT index > 2.
  • 12. Distance from target Distance from target Percentage of practices more than  Percentage of practices more than x% away from target > +/‐ 5% > +/‐ 10% > +/‐ 20% DFT relative to PCT  mean  61.1 34.6 14.0 DFT relative to national  mean  72.5 48.9 20.9 12
  • 13. Phase III Objectives: in progress Phase III Objectives: in progress • Refresh existing PBRA model using more Refresh existing PBRA model using more  recent data (for allocations 2011/12) • Develop improved PBRA model (for allocations Develop improved PBRA model (for allocations  2012/13)  • Model a variety of risk sharing arrangements Model a variety of risk sharing arrangements  (to inform shadow GP Consortia and NHS  Commissioning Board) • Develop a final PBRA formula (for allocations  2013/14)
  • 14. Basic model Explanatory variables Prediction variable 2007/08 2008/09 2009/10
  • 15. Data lag 2007/08 2008/09 2009/10 2010/11 2011/12 2012/13
  • 16. GP budgets and risk: we’ve been here before ’ b h b f • GP fundholding c.1991 g • Total fundholding c.1995 • ‘Primary Care Groups’ c.1998 • Practice based commissioning c.2002 Martin, S., Rice, N. and Smith, P. (1998), “Risk and the general  practitioner budget holder”, Social Science and Medicine, 47(10),  1547‐1554. Smith, P. (1999), “Setting budgets for general practice in the New NHS”,  British Medical Journal, 318, 776‐779.
  • 17. Fundholding • Relatively generous budgets Relatively generous budgets • Limited set of elective conditions plus  prescribing covered prescribing covered • Per patient limit £6000 • Overspends largely borne by Health Authority • Underspends kept by practice for patient  p p yp p services • A very ‘soft’ budget A very  soft budget
  • 18. Decomposing the variation in practice  expenditure  d • The formula captures average clinical responses  p g p to measured patient and area characteristics.  Therefore any variation from the formula will be  due to: due to: – Variations in clinical practice; – Variations in the prices of treatments used by the  practice; – Imperfections in the formula caused by known patient  characteristics that are not captured in the formula; p ; – Random (chance) variations in levels of sickness  within the practice population.
  • 19. High cost cases High cost cases practices umber of p Nu Percentage of cases over £20K per person per year 19
  • 20. Sampled from patients (10m) within a 20% random sample of all patients 100 replications for each consortium size Consortium size increased in units of 10,000 40 Consortia risk profile p sortium risk per capita(£) Upper 95% C.I. 20 14 0 Average risk ‐13.5 -20 - Cons Lower 95% C.I. -40 0 100000 200000 300000 400000 500000 Consortium list size Average risk Lower CI Upper CI Simulations from all data Risk smoothed over time - predicted versus actual expenditure
  • 21. Consortia risk profile Consortium size Consortium size 10000 100000 .6 .6 .4 .4 .2 .2 0 0 ability 0 2 4 6 8 10 0 2 4 6 8 10 Proba Consortium size Consortium size 300000 500000 .6 .6 .4 4 .4 4 .2 .2 0 0 0 2 4 6 8 10 0 2 4 6 8 10 Percentage Variation Simulations from all data Probability f P b bilit of more th an X percent variation f than t i ti from annual b d t l budget Acknowledgement: Nigel Rice and Hugh Gravelle
  • 22. Consortia risk profile Consortium size Consortium size 10000 50000 .6 .6 .4 .4 .2 .2 0 0 obability 0 2 4 6 8 10 0 2 4 6 8 10 Consortium size Consortium size Pro 100000 150000 .6 .6 .4 .4 .2 2 .2 2 0 0 0 2 4 6 8 10 0 2 4 6 8 10 Percentage Variation Omit £100k Omit £150k Probability of more than an X percent variation from annual budget Simulations omitting hi h cost patients f Si l ti itti high t ti t from practice li t ti lists Acknowledgement: Nigel Rice and Hugh Gravelle
  • 23. Some possible consequences of ‘hard’  budget constraints b d • Practices that perceive that their expenditure will fall below their  budget may “spend up” in order to protect their budgetary position  b d t “ d ”i d t t t th i b d t iti in future years; • Practices that perceive that their expenditure will exceed their  budget may be thrown into crisis as they seek to conform to the  budget may be thrown into crisis as they seek to conform to the budget; • Patients may be treated inequitably.  Different practices will be  under different budgetary pressures, and so may adopt different  treatment practices.   • Within a practice, choice of treatment may vary over the course of  a year if the practice’s perception of its budgetary position changes. • G General practices may adopt a variety of defensive stratagems, such  l i d i fd f i h as cream skimming patients they perceive to be healthier than  implied by their capitation payment.
  • 24. Some budgetary risk management  strategies • Pooling practices • Pooling years • Excluding predictably expensive patients • ‘Carving out’ certain procedures or services Carving out certain procedures or services • Analysis of reasons for variations from budgets • Allowing some reinsurance of risk – Limiting liability on individual episode – Limiting liability on individual patient – Risk sharing – Retention of a contingency fund – Etc • Making sanctions and rewards proportionate g p p